Björn Dahlbäck

Björn Dahlbäck (born 1949) is a Swedish physician, medical researcher, and professor of clinical chemistry, specializing in hematology and the molecular mechanisms of blood coagulation.[1] He is perhaps "best known for his groundbreaking discovery of activated protein C (APC) resistance as the most common inherited risk factor of venous thrombosis."[2]

Björn Dahlbäck (2014)

Education and career

Dahlbäck graduated with an M.D. from Lund University and then completed his medical internship and residency at Malmö's University Hospital,[2] which is now merged into Skåne University Hospital. In 1981 he received from Lund University his doctorate with dissertation The activation of prothrombin on the platelet surface[3] under the supervision of Johan Stenflo. Dahlbäck was a postdoc at La Jolla's Scripps Research, where his supervisor was Hans J. Müller-Eberhard, and later was a visiting scholar at Oklahoma Medical Research Foundation (OMRF). In 1989 at Lund University, Dahlbäck was appointed a full professor of clinical chemistry, specializing in hematology and cardiac and cardiovascular systems.[2][1] He is also the director of the blood coagulation unit at Malmö General Hospital.[4]

His research was important in showing that APC resistance is caused by a harmful mutation in the F5 gene corresponding to the protein Factor V; the specific mutation was subsequently identified by several groups of researchers and is now called Factor V Leiden.[2] In 2013, Dahlbäck and colleagues identified the F5 gene mutation that causes the phenotype called "east Texas bleeding disorder".[5][2]

Other achievements include the first purification of human FV, the discovery of the complex between protein S and the complement regulator C4BP, identification and cloning of the protein S-binding beta-chain of C4BP, electron microscopy visualization of the spider-like C4BP, sequencing and cloning of protein S, and the creation of Gas6 knockout mice. A noteworthy achievement outside the coagulation field is the identification of apoM, an HDL-associated apolipoprotein, and the discovery that it is the carrier of sphingosine 1-phosphate in the blood.[2]

He has received several honors and awards,[2] including in 1996 the Louis-Jeantet Prize for Medicine[4] and in 2019 H. M. The King's Medal (H.M. Konungens Medalj) of the 12th size from the Royal Court of Sweden.[6] He is a member of the Royal Swedish Academy of Sciences.[7]

In 2000, Academic Press published Hematology: Landmark Papers of the Twentieth Century , which included the 1994 paper Resistance to activated protein C as a basis for venous thrombosis by Peter J. Svensson and Björn Dahlbäck.[8][9]

Selected publications

References
  1. "Björn Dahlbäck, Senior Professor". Lund University.
  2. "Björn Dahlbäck, Biography". eMedEvents.
  3. Dahlbäck, Björn (1981). The activation of prothrombin on the platelet surface. Malmö.
  4. "Professeur Björn Dahlbäck, Laureate de Prix Louis-Jeantet de médecine 1996". Fondation Louis-Jeantet. October 2017. (in French)
  5. Vincent, Lisa M.; Tran, Sinh; Livaja, Ruzica; Bensend, Tracy A.; Milewicz, Dianna M.; Dahlbäck, Björn (2013). "Coagulation factor VA2440G causes east Texas bleeding disorder via TFPIα". Journal of Clinical Investigation. 123 (9): 3777–3787. doi:10.1172/JCI69091. PMC 3754264. PMID 23979162.
  6. "H.M. Konungens Medalj". Sveriges Kungahaus. June 6, 2019.
  7. "Björn Dahlbäck". Kungliga Vetenskaps Akademien.
  8. Lichtman, Marshall A.; Boxer, Laurence A.; Spivak, Jerry L.; Henderson, Edward; Shattil, Sanford J., eds. (27 April 2000). Hematology: Landmark Papers of the Twentieth Century. Academic Press. ISBN 9780124485105.
  9. Svensson, Peter J.; Dahlback, Bjorn (1994). "Resistance to Activated Protein C as a Basis for Venous Thrombosis". New England Journal of Medicine. 330 (8): 517–522. doi:10.1056/NEJM199402243300801. PMID 8302317.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.